What are lurbinectedin's potential contraindications?

Lurbinectedin has a few clear contraindications in standard prescribing information. The main ones are:

- Hypersensitivity: Do not use in patients with a known hypersensitivity to lurbinectedin or to any of its excipients.

- Severe hepatic impairment: Lurbinectedin is primarily cleared by the liver, and its use is not recommended in patients with severe hepatic impairment (typically described as Child-Pugh C).

- Concomitant strong CYP3A inhibitors: The label generally advises against giving lurbinectedin together with strong inhibitors of CYP3A (because they markedly raise lurbinectedin exposure and toxicity).

Notes:
- Regions may have slight differences in labeling, so it’s best to check the exact prescribing information for your country (FDA label in the U.S., EMA label in Europe, etc.).
- There are also cautions and monitoring considerations (hematologic toxicity, hepatotoxicity, etc.) and certain cautions around pregnancy, but the above are the primary contraindications.

If you share your region or a specific patient scenario, I can pull more precise wording from the current labeling.